Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients

Journal of Affective Disorders

Volumn 175, Issue , 2015, Pages 233-240

  Colle, Romain ^a   Gressier, Florence ^a   Verstuyft, Céline ^b,c   Deflesselle, Eric ^a   Lépine, Jean Pierre ^d   Ferreri, Florian ^e   Hardy, Patrick ^a   Guilloux, Jean Philippe ^f   Petit, Anne Cécile ^a   Fève, Bruno ^g   Falissard, Bruno ^h   Becquemont, Laurent ^b,c   Corruble, Emmanuelle ^a  

^a BICÊTRE HOSPITAL   (France)

^b INSERM U1184   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f INSERM   (France)

^g CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Antidepressant; BDNF; Major depressive disorder; Remission; Response; Val66Met polymorphism

Indexed keywords

ADVERSE DRUG REACTION; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN-DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CLOMIPRAMINE; DRUG THERAPY; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADOLESCENT; ADULT; AGED; ALLELE; ALLELES; ARTICLE; CAUCASIAN; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DNA POLYMORPHISM; DRUG THERAPY; DRUG TREATMENT FAILURE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETICS; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMANS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PRIORITY JOURNAL; PROSPECTIVE STUDIES; PROSPECTIVE STUDY; REMISSION; REMISSION INDUCTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; YOUNG ADULT;

ADOLESCENT; ADULT; ADVERSE EFFECTS; AGED; ALLELES; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETICS; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; REMISSION INDUCTION; THERAPEUTIC USE; YOUNG ADULT;

EID: 84964239589     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2015.01.013     Document Type: Article

References (47)

1. G.S. Alexopoulos, C.E. Glatt, M.J. Hoptman, D. Kanellopoulos, C.F. Murphy, R.E. Kelly Jr., S.S. Morimoto, K.O. Lim, and F.M. Gunning BDNF Val66Met polymorphism, white matter abnormalities and remission of geriatric depression J. Affect. Disord. 125 2010 262 268
2. I.M. Anderson SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability Depress. Anxiety 7 1998 11 17
3. K.G. Bath, D.Q. Jing, I. Dincheva, C.C. Neeb, S.S. Pattwell, M.V. Chao, F.S. Lee, and I. Ninan BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity Neuropsychopharmacology 37 2012 1297 1304
4. O. Berton, C.A. McClung, R.J. Dileone, V. Krishnan, W. Renthal, S.J. Russo, D. Graham, N.M. Tsankova, C.A. Bolanos, M. Rios, L.M. Monteggia, D.W. Self, and E.J. Nestler Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress Science 311 2006 864 868
5. A.R. Brunoni, A.H. Kemp, P. Shiozawa, Q. Cordeiro, L.C. Valiengo, A.C. Goulart, B. Coprerski, P.A. Lotufo, D. Brunoni, A.B. Perez, F. Fregni, and I.M. Benseñor Impact of 5-HTTLPR and BDNF polymorphisms on response to sertraline versus transcranial direct current stimulation: implications for the serotonergic system Eur. Neuropsychopharmacol. 23 2013 1530 1540
6. J.D. Bukh, C. Bock, M. Vinberg, T. Werge, U. Gether, and L.V. Kessing No interactions between genetic polymorphisms and stressful life events on outcome of antidepressant treatment Eur. Neuropsychopharmacol. 20 2010 327 335
7. F. Calabrese, R. Molteni, P.F. Maj, A. Cattaneo, M. Gennarelli, G. Racagni, and M.A. Riva Chronic duloxetine treatment induces specific changes in the expression of BDNF transcripts and in the subcellular localization of the neurotrophin protein Neuropsychopharmacology 32 2007 2351 2359
8. M.H. Chi, H.H. Chang, S.Y. Lee, I.H. Lee, P.W. Gean, Y.K. Yang, R.B. Lu, and P.S. Chen Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder J. Affect. Disord. 126 2010 430 435
9. M.J. Choi, R.H. Kang, S.W. Lim, K.S. Oh, and M.S. Lee Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder Brain Res. 1118 2006 176 182
10. J.D. Cooke, L.M. Grover, and P.R. Spangler Venlafaxine treatment stimulates expression of brain-derived neurotrophic factor protein in frontal cortex and inhibits long-term potentiation in hippocampus Neuroscience 162 2009 1411 1419
11. L. Coulbault, M. Beaussier, C. Verstuyft, H. Weickmans, L. Dubert, D. Trégouet, C. Descot, Y. Parc, A. Lienhart, P. Jaillon, and L. Becquemont Environmental and genetic factors associated with morphine response in the postoperative period Clin. Pharmacol. Ther. 79 2006 316 324
12. R.B. D'Agostino Jr, and R.B. D'Agostino Sr. Estimating treatment effects using observational data JAMA 297 2007 314 316
13. Danish University Antidepressant Group Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study J. Affect. Disord. 18 1990 289 299
14. K. Domschke, B. Lawford, G. Laje, K. Berger, R. Young, P. Morris, J. Deckert, V. Arolt, F.J. McMahon, and BT. Baune Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response Int. J. Neuropsychopharmacol. 13 2010 93 101
15. M.F. Egan, M. Kojima, J.H. Callicott, T.E. Goldberg, B.S. Kolachana, A. Bertolino, E. Zaitsev, B. Gold, D. Goldman, M. Dean, B. Lu, and D.R. Weinberger The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function Cell 112 2003 257 269
16. W. El-Hage, P. Vourc'h, P. Gaillard, J. Léger, C. Belzung, Y. Ibarguen-Vargas, C.R. Andres, and V. Camus The BDNF Val66Met polymorphism is associated with escitalopram response in depressed patients Psychopharmacology 232 2015 575 581
17. T. Frodl, C. Schüle, G. Schmitt, C. Born, T. Baghai, P. Zill, R. Bottlender, R. Rupprecht, B. Bondy, M. Reiser, H.J. Möller, and E.M. Meisenzahl Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression Arch. Gen. Psychiatry 64 2007 410 416
18. A. Govindarajan, B.S. Rao, D. Nair, M. Trinh, N. Mawjee, S. Tonegawa, and S. Chattarji Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects Proc. Natl. Acad. Sci. USA 103 2006 13208 13213
19. Guy, W., 1976. Clinical Global Impressions, ECDEU Assessment Manual for Psychopharmacology. (1st ed). MD: US Dept. of Health, Education and Welfare, ADAMHA, MIMH Psychopharmacology Research Branch, Rockville, pp. 218-222.
20. M. Hamilton A rating scale for depression J. Neurol. Neurosurg. Psychiatry 23 1960 56 62
21. S. Henningsson, J. Borg, J. Lundberg, J. Bah, M. Lindström, E. Ryding, H. Jovanovic, T. Saijo, M. Inoue, I. Rosén, L. Träskman-Bendz, L. Farde, and E. Eriksson Genetic variation in brain-derived neurotrophic factor is associated with serotonin transporter but not serotonin-1A receptor availability in men Biol. Psychiatry 2009 66 2009 477 485
22. J.G. Hensler, T. Advani, and L.M. Monteggia Regulation of serotonin-1A receptor function in inducible brain-derived neurotrophic factor knockout mice after administration of corticosterone Biol. Psychiatry 62 2007 521 529
23. Y. Ji, J.M. Biernacka, S. Hebbring, Y. Chai, G.D. Jenkins, A. Batzler, K.A. Snyder, M.S. Drews, Z. Desta, D. Flockhart, T. Mushiroda, M. Kubo, Y. Nakamura, N. Kamatani, D. Schaid, R.M. Weinshilboum, and D.A. Mrazek Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics Pharmacogenomics J. 13 2013 456 463
24. AV. Avgustinovich Kalueff, D.F. Kudryavtseva, and N.N. Murphy. BDNF in anxiety and depression Science 312 2006 1598 1599
25. R.H. Kang, H.S. Chang, M.L. Wong, M.J. Choi, J.Y. Park, H.Y. Lee, I.K. Jung, S.H. Joe, L. Kim, S.H. Kim, Y.K. Kim, C.S. Han, B.J. Ham, H.J. Lee, Y.H. Ko, M.S. Lee, and M.S. Lee Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression J. Psychopharmacol. 24 2010 1755 1763
26. M. Kato, and A. Serretti Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder Mol. Psychiatry 15 2010 473 500
27. A. Katsuki, R. Yoshimura, T. Kishi, H. Hori, W. Umene-Nakano, A. Ikenouchi-Sugita, K. Hayashi, K. Atake, N. Iwata, and J. Nakamura Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD) CNS Spectr. 17 2012 155 163
28. N.A. Kocabas, I. Antonijevic, C. Faghel, C. Forray, S. Kasper, Y. Lecrubier, S. Linotte, I. Massat, J. Mendlewicz, M. Noro, S. Montgomery, P. Oswald, L. Snyder, J. Zohar, and D. Souery Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder Int. Clin. Psychopharmacol. 26 2011 1 10
29. K.L. Lanctôt, M.J. Rapoport, F. Chan, R.D. Rajaram, J. Strauss, T. Sicard, S. McCullagh, A. Feinstein, A. Kiss, J.L. Kennedy, A.S. Bassett, and N. Herrmann Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury Brain Inj. 24 2010 959 969
30. J. Licinio, C. Dong, and M.L. Wong Novel sequence variations in the brain derived neurotrophic factor (BDNF) gene and association with major depression and antidepressant treatment response Arch. Gen. Psychiatry 66 2009 488 497
31. F. Matrisciano, S. Bonaccorso, A. Ricciardi, S. Scaccianoce, I. Panaccione, L. Wang, A. Ruberto, R. Tatarelli, F. Nicoletti, P. Girardi, and R.C. Shelton Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine J. Psychiatr. Res. 43 2009 247 254
32. M.L. Molendijk, B.A. Bus, P. Spinhoven, B.W Penninx, G. Kenis, J. Prickaerts, R.C. Oude Voshaar, and B.M. Elzinga Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment Mol. Psychiatry 16 2011 1088 1095
33. Musil, R., Zill, P., Seemüller, F., Bondy, B., Obermeier, M., Spellmann, I., Bender, W., Adli, M., Heuser, I., Zeiler, J., Gaebel, W., Maier, W., Rietschel, M., Rujescu, D., Schennach, R., Möller, H.J., Riedel, M., 2013.No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression. Eur. Arch. Psychiatry Clin. Neurosci. 263, 405-412.
34. T. Niitsu, C. Fabbri, F. Bentini, and A. Serretti Pharmacogenetics in major depression: a comprehensive meta-analysis Prog. Neuropsychopharmacol. Biol. Psychiatry 45 2013 183 194
35. S. Sen, R. Duman, and G. Sanacora Serum BDNF, depression and antidepressant medications: meta-analyses and implications Biol. Psychiatry 64 2008 527 532
36. N. Su, L. Zhang, F. Fei, H. Hu, K. Wang, H. Hui, X.F. Jiang, X. Li, H.N. Zhen, J. Li, B.P. Cao, W. Dang, Y. Qu, and F. Zhou The brain-derived neurotrophic factor is associated with alcohol dependence-related depression and antidepressant response Brain Res. 1415 2011 119 126
37. W.D. Taylor, D.R. McQuoid, A. Ashley-Koch, J.R. MacFall, J. Bridgers, R.R. Krishnan, and D.C. Steffens BDNF Val66Met genotype and 6-month remission rates in late-life depression Pharmacogenomics J. 11 2011 146 154
38. M.H. Trivedi, A.J. Rush, S.R. Wisniewski, A.A. Nierenberg, D. Warden, L. Ritz, G. Norquist, R.H. Howland, B. Lebowitz, P.J. McGrath, K. Shores-Wilson, M.M. Biggs, G.K. Balasubramani, M. Fava STAR∗D Study Team Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice Am. J. Psychiatry 163 2006 28 40
39. S.J. Tsai, C.Y. Cheng, Y.W. Yu, T.J. Chen, and C.J. Hong Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response Am. J. Med. Genet. B. Neuropsychiatr. Genet. 123 2003 19 22
40. M.J. Wilkie, D. Smith, I.C. Reid, R.K. Day, K. Matthews, C.R. Wolf, D. Blackwood, and G. Smith A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression Pharmacogenet. Genomics 17 2007 207 215
41. G. Xu, K. Lin, D. Rao, Y. Dang, H. Ouyang, G. Mai, and M. Zhang Brain-derived neurotrophic factor gene polymorphism (Val66Met) and the early response to antidepressant in Chinese Han population Psychiatr. Genet. 22 2012 214 215
42. T. Yan, L. Wang, W. Kuang, J. Xu, S. Li, J. Chen, and Y. Yang Brain-derived neurotrophic factor Val66Met polymorphism association with antidepressant efficacy: a systematic review and meta-analysis Asia Pac. Psychiatry 6 2014 241 251
43. K. Yoshida, H. Higuchi, M. Kamata, H. Takahashi, K. Inoue, T. Suzuki, K. Itoh, and N. Ozaki The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine J. Psychopharmacol. 21 2007 650 656
44. R. Yoshimura, T. Kishi, A. Suzuki, W. Umene-Nakano, A. Ikenouchi-Sugita, H. Hori, K. Otani, N. Iwata, and J. Nakamura The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 1022 1025
45. H. Yu, D.D. Wang, Y. Wang, T. Liu, F.S. Lee, and Z.Y. Chen Variant brain-derived neurotrophic factor Val66Met polymorphism alters vulnerability to stress and response to antidepressants J. Neurosci. 32 2012 4092 4101
46. Y,F Zou, D.Q. Ye, X.L. Feng, H. Su, F.M. Pan, and F.F. Liao Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder Eur. Neuropsychopharmacol. 20 2010 535 544
47. Y.F. Zou, Y. Wang, P. Liu, X.L. Feng, B.Y. Wang, T.H. Zang, X. Yu, J. Wei, Z.C. Liu, Y. Liu, M. Tao, H.C. Li, K.Q. Li, J. Hu, M. Li, K.R. Zhang, D.Q. Ye, and X.P. Xu Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine Hum. Psychopharmacol. 25 2010 145 152